StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
10
Publishing Date
2022 - 12 - 16
1
2021 - 11 - 15
1
2021 - 11 - 02
1
2021 - 09 - 09
1
2021 - 06 - 02
1
2021 - 05 - 18
1
2021 - 03 - 11
1
2021 - 03 - 09
2
2020 - 12 - 17
1
Sector
Health technology
10
Tags
Active
1
Agreement
1
Biocanada
1
Biopharma
1
Bioscience
1
Biotech-bay
1
Biotech-beach
1
Clinical-trials-phase-ii
3
Commercialization
1
Companies
2
Conference
4
Designation
1
Diabetes
4
Disease
3
Enroll
3
Europe
1
Fast track
1
Fast track designation
1
Fda
1
Fda fast track
1
Financial results
2
Growth
2
Hepatitis
1
Key
1
Life science
1
Liver
3
Lone-star-bio
1
Lupus
1
Market
3
Met642
9
Milestone
1
N/a
32
Nash
9
Phase 1
2
Phase 2
10
Phase 2b
8
Phase 3
2
Positive
2
Positive results
1
Pre-clinical
2
Preclinical
2
Presentation
3
Rapid
1
Research
1
Results
12
Study
2
Therapeutics
1
Topline
2
Treatment
3
Trial
10
Ulcerative colitis
1
Entities
Equillium, inc.
1
Metacrine, inc.
10
Symbols
ADVM
8
ADXN
8
ADXS
9
AGNPF
19
ALDX
9
ALNY
11
ALT
12
AMGN
15
ARWR
17
ATHA
10
ATHE
25
ATOS
11
AVXL
11
AYLA
14
BBIO
11
BGNE
8
BIIB
13
BIVI
8
BMY
15
BPTS
8
BRTX
10
CGTX
8
CLNN
15
CVAC
11
DNLI
8
DVAX
12
ELOX
11
ENTX
8
EVLO
9
FNCTF
8
FWBI
13
GILD
9
GLTO
8
GTHX
9
HEPA
10
IBRX
11
IDYA
13
IMAB
26
IMUX
11
INCY
19
JNJ
28
KTRA
8
LGVN
13
LLY
34
LPCN
8
MDWD
13
MRNA
13
MTCR
10
MYMD
8
OCUP
12
PDSB
15
PFE
12
PTGX
10
RARE
8
RDHL
16
SNY
43
SNYNF
28
SRNE
20
SWTX
9
VIR
10
Exchanges
Nasdaq
10
Crawled Date
2022 - 12 - 16
1
2021 - 11 - 15
1
2021 - 11 - 02
1
2021 - 09 - 09
1
2021 - 06 - 02
1
2021 - 05 - 18
1
2021 - 03 - 11
1
2021 - 03 - 09
2
2020 - 12 - 17
1
Crawled Time
12:00
2
12:01
1
12:15
3
14:23
1
18:00
3
Source
www.biospace.com
3
www.globenewswire.com
6
www.metacrine.com
1
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Phase 2
symbols :
Mtcr
save search
Equillium’s Partner Biocon Initiates Phase 2 Study of Itolizumab in Ulcerative Colitis
Published:
2022-12-16
(Crawled : 18:00)
- biospace.com/
EQ
|
$1.85
0.0%
93K
|
Health Technology
|
54.81%
|
O:
-0.33%
H:
0.76%
C:
-3.44%
study
phase 2
ulcerative colitis
Metacrine Reports Topline Results for MET409 Phase 2a Combination Trial In Patients with Type 2 Diabetes and NASH
Published:
2021-11-15
(Crawled : 18:00)
- metacrine.com
MTCR
|
$0.5814
-5.14%
84K
|
Health Technology
|
-53.49%
|
O:
1.6%
H:
2.36%
C:
-0.79%
diabetes
phase 2
results
topline
nash
trial
phase 2b
Metacrine Reports Topline Results for MET409 Phase 2a Combination Trial In Patients with Type 2 Diabetes and NASH
Published:
2021-11-02
(Crawled : 18:00)
- biospace.com/
MTCR
|
$0.5814
-5.14%
84K
|
Health Technology
|
-59.06%
|
O:
0.0%
H:
4.48%
C:
-4.23%
diabetes
phase 2
results
topline
nash
trial
phase 2b
Metacrine Achieves Full Enrollment for MET642 Phase 2a Trial in Patients With Nash
Published:
2021-09-09
(Crawled : 12:15)
- globenewswire.com
MTCR
|
$0.5814
-5.14%
84K
|
Health Technology
|
-80.42%
|
O:
1.01%
H:
4.0%
C:
0.0%
phase 2
nash
trial
met642
phase 2b
enroll
Metacrine Achieves Full Enrollment for MET409 Phase 2a Combination Trial in Patients With Type 2 Diabetes and NASH
Published:
2021-06-02
(Crawled : 12:15)
- globenewswire.com
MTCR
|
$0.5814
-5.14%
84K
|
Health Technology
|
-85.78%
|
O:
0.73%
H:
0.0%
C:
-2.67%
diabetes
phase 2
nash
trial
phase 2b
enroll
Metacrine Achieves Enrollment Target for MET642 Phase 2a Trial Interim Analysis
Published:
2021-05-18
(Crawled : 12:15)
- globenewswire.com
MTCR
|
$0.5814
-5.14%
84K
|
Health Technology
|
-84.07%
|
O:
0.0%
H:
3.01%
C:
0.27%
phase 2
trial
met642
phase 2b
enroll
Metacrine to Present Final Results from Phase 1 Trial of MET642, an Optimized FXR Agonist, at the 2021 NASH-TAG Conference
Published:
2021-03-11
(Crawled : 12:00)
- globenewswire.com
MTCR
|
$0.5814
-5.14%
84K
|
Health Technology
|
-93.26%
|
O:
1.97%
H:
4.55%
C:
-5.0%
phase 1
results
trial
phase 3
phase 2
met642
nash
Metacrine Initiates Phase 2a Trial of MET642 for the Treatment of Patients with NASHOn-track for Interim Analysis Readout in the Fourth Quarter of 2021
Published:
2021-03-09
(Crawled : 14:23)
- biospace.com/
MTCR
|
$0.5814
-5.14%
84K
|
Health Technology
|
-93.35%
|
O:
1.83%
H:
6.74%
C:
2.25%
treatment
phase 2
trial
met642
phase 2b
Metacrine Initiates Phase 2a Trial of MET642 for the Treatment of Patients with NASH
Published:
2021-03-09
(Crawled : 12:00)
- globenewswire.com
MTCR
|
$0.5814
-5.14%
84K
|
Health Technology
|
-93.35%
|
O:
1.83%
H:
6.74%
C:
2.25%
treatment
phase 2
trial
met642
nash
phase 2b
Metacrine Reports Positive Results from Phase 1 Trial of MET642
Published:
2020-12-17
(Crawled : 12:01)
- globenewswire.com
MTCR
|
$0.5814
-5.14%
84K
|
Health Technology
|
-94.07%
|
O:
4.18%
H:
2.64%
C:
-5.19%
results
positive results
positive
trial
phase 3
phase 1
phase 2
met642
Gainers vs Losers
56%
44%
Top 10 Gainers
INVO
|
$1.76
131.58%
56.82%
230M
|
Health Technology
SINT
|
$0.0365
59.39%
37.26%
470M
|
Health Technology
WISA
4
|
$9.19
50.66%
33.7%
65M
|
Electronic Technology
EDBL
|
News
|
$6.73
47.91%
32.39%
13M
|
GCTK
|
$0.715
36.27%
26.62%
640K
|
Manufacturing
TCON
|
$2.33
36.26%
26.61%
2M
|
Health Technology
TIRX
|
$0.48
6.43%
24.58%
4.8M
|
KZIA
|
$0.38
30.58%
23.42%
300K
|
Health Technology
VNDA
|
News
|
$5.23
29.14%
22.56%
24M
|
Health Technology
ATNF
|
$1.91
29.05%
22.51%
310K
|
Your saved searches
Save your searches and get alerts when important news are released.